Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia.

导出 OA

翻译打印收藏纠错

作者： Fadima C,Haidara ^[1] ; Ama,Umesi ^[1] ; Samba O,Sow ^[1] ; Magnus,Ochoge ^[1] ; Fatoumata,Diallo ^[1] ; Abdulazeez,Imam ^[1] ; Youssouf,Traore ^[1] ; Lucy,Affleck ^[1] ; Moussa F,Doumbia ^[1] ; Bubacarr,Daffeh ^[1] ; Mamoudou,Kodio ^[1] ; Oghenebrume,Wariri ^[1] ; Awa,Traoré ^[1] ; Edrissa,Jallow ^[1] ; Beate,Kampmann ^[1] ; Dhananjay,Kapse ^[1] ; Prasad S,Kulkarni ^[1] ; Asha,Mallya ^[1] ; Sunil,Goel ^[1] ; Pankaj,Sharma ^[1] ; Annamraju D,Sarma ^[1] ; Nikhil,Avalaskar ^[1] ; F Marc,LaForce ^[1] ; Mark R,Alderson ^[1] ; Abdi,Naficy ^[1] ; Steve,Lamola ^[1] ; Yuxiao,Tang ^[1] ; Lionel,Martellet ^[1] ; Nancy,Hosken ^[1] ; Evangelos,Simeonidis ^[1] ; Jo Anne,Welsch ^[1] ; Milagritos D,Tapia ^[1] ; Ed,Clarke ^[1]

作者单位： From Centre pour le Développement des Vaccins du Mali, Bamako (F.C.H., S.O.S., F.D., Y. Traore, M.F.D., M.K., A.T., M.D.T.); Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, Gambia (A.U., M.O., A.I., L.A., B.D., O.W., E.J., B.K., E.C.); the Serum Institute of India, Pune (D.K., P.S.K., A.M., S.G., P.S., A.D.S., N.A., F.M.L.); the Center for Vaccine Innovation and Access, PATH (formerly known as the Program for Appropriate Technology in Health), Seattle (M.R.A., A.N., S.L., Y. Tang, L.M., N.H., E.S., J.A.W.); and the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.). ^[1]